✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
The GH fell from a basal level of 18.5±8.3 ng/ml to 7.7±4.3 ng/ml after 1 month (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:In order to contirm the effectiveness and tolerability of octreotide in acromegaly, we studied seven patients (4 women, 3 men) after unsuccessful surgery and radiotherapy performed for pituitary adenomas.
📊
Key Findings & Data:The patients (29.6±7.9 yr) were treated with octreotide at doses of 300-1500 1g daily for 12 months.
💡
Conclusion & Impact:The GH fell from a basal level of 18.5±8.3 ng/ml to 7.7±4.3 ng/ml after 1 month (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
In order to contirm the effectiveness and tolerability of octreotide in acromegaly, we studied seven patients (4 women, 3 men) after unsuccessful surgery and radiotherapy performed for pituitary adenomas. The patients (29.6±7.9 yr) were treated with octreotide at doses of 300-1500 1g daily for 12 months. Hormonal profiles and ultrasonographic evaluation of gallbladder were performed before the treatment, after 1 month, and subsequently at intervals of 36 months. The GH fell from a basal level of 18.5±8.3 ng/ml to 7.7±4.3 ng/ml after 1 month (p
🔖
Cite This Article
ERBAŞ, T., AKALIN, S., GEDİK, O., ÖZMEN, M. (2022). Long-term treatment of acromegaly with octreotide. Turkish Journal of Medical Sciences, Cilt: 27 - Sayı: 6, 519–521. https://ajindex.com/articles/612709